Adam Smith, MD
Pulmonary Disease · Burlington, MANPI 1962734368
Payments from drug & device makers
Across 680 payments — averaging $435.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$120K
- AstraZeneca$73K
- Boehringer Ingelheim$29K
- Regeneron Healthcare Solutions, Inc.$25K
- Insmed, Inc.$15K
- Regeneron$7K
- plus $28K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 180 | $119,815 |
| AstraZeneca | 257 | $73,142 |
| Boehringer Ingelheim | 63 | $28,823 |
| Regeneron Healthcare Solutions, Inc. | 40 | $24,740 |
| Insmed, Inc. | 21 | $14,730 |
| Regeneron | 12 | $6,538 |
| Novartis | 6 | $5,707 |
| Verona Pharma, Inc. | 11 | $5,124 |
| Mylan Specialty L.p. | 9 | $3,769 |
| Noah Medical Corporation | 8 | $3,261 |
| Roche Products Limited | 3 | $2,751 |
| Gyrus ACMI, Inc. | 3 | $2,237 |
| Radiometer America, Inc | 1 | $1,950 |
| BD | 1 | $850 |
| Amgen | 32 | $767 |
| Ambu A/s | 1 | $750 |
| Baxter Healthcare | 1 | $300 |
| United Therapeutics Corporation | 7 | $202 |
| Sanofi | 8 | $192 |
| Philips North America LLC | 5 | $184 |
| Galvanize Therapeutics, Inc | 1 | $79 |
| Genentech USA, Inc. | 4 | $69 |
| Astellas Pharma US Inc | 2 | $51 |
| Tactile Systems Technology Inc | 1 | $50 |
| Sunovion Pharmaceuticals Inc. | 2 | $46 |
| Pfizer | 1 | $22 |
How this compares
$296,148 in reported general payments places this provider in the 90th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Burlington
- Carla LambBurlington$185K
- Timothy LieschingBurlington$147K
- Aaron WaxmanBoston$7.7M
- John BerkBoston$6M
- Darrell KottonBoston$5.3M
- Hilary GoldbergBoston$3.5M
- Ehab BillatosWinchester$2.7M
- Harrison FarberBoston$2.6M
- Elizabeth KlingsBoston$2.1M
- Curtis MelloNorth Dartmouth$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.